Global CyberKnife Market Size, Trend & Opportunity Analysis Report, by Application (Tumour, Cancer, Vascular Malformation), End Use (Hospitals, Outpatient Facilities, Research & Manufacturing), and Forecast, 2024–2035

Market Definition and Introduction

The global CyberKnife market was valued at USD 637.4 million in 2024 and is anticipated to reach USD 3,792.21 million by 2035, expanding at a CAGR of 17.6% during the forecast period (2024–2035). Traditionally, radiation oncology and neurosurgery have been based on imprecise treatment methods. However, the technological revolution in the healthcare ecosystem has given rise to CyberKnife-like precision treatment modalities, bringing new definitions to the discipline. The cutting-edge device is an advanced robotic radiosurgery system that has acquired a pivotal position for the non-invasive treatment of tumours, cancers, and vascular malformations. Its acceptance was strongly propelled by the ever-increasing burden of cancer in the world, combined with the clinical urge for targeted therapies with an extremely high degree of accuracy and with minimal collateral damage to host tissues.

The rising rates of brain, lung, prostate, and liver cancers have similarly called for radiation technology that shall spare damage and maximise survival probabilities for the patients. The commercial applicability of the CyberKnife systems fits in tightly with the clinical demands of robotic accuracy and real-time imaging. As hospitals and outpatient clinics begin to integrate the CyberKnife procedure with various treatment pathways due to the system's ability to deliver hypofractionated radiation doses without surgical incision, its use will increase. Additionally, with the convergence of artificial intelligence and image-guided robotics, cytokinesis elevated targeting performance with sub-millimetre accuracy.

On the supply side, an accelerated wave of collaboration between device manufacturers, oncology centres, and research institutes is underway toward improving treatment protocols and increasing clinical acceptance. Not only are technology upgrades shaping the competitive landscape of CyberKnife systems, but also the regulatory approvals and capital investment in cancer treatment infrastructure worldwide. The emerging markets are strategically positioning the CyberKnife system toward two major objectives: to better healthcare and attract international patients under medical tourism. Hence, the global market for CyberKnife systems is transitioning toward mainstream acceptance, fundamentally altering cancer care at the interface of robotics, radiation, and precision medicine.

Recent Developments in the Industry

Accuray is extending the capabilities of CyberKnife with artificial intelligence contributions to the workflow.

In March 2024, Accuray Incorporated announced an update for workflow solutions within the CyberKnife platform with artificial intelligence integration for fast treatment planning and execution. This innovation is targeting the reduction of the clinician's workload while maintaining treatment accuracy.

Elekta collaborates with academic hospitals for radiosurgery research trials.

In June 2024, Elekta AB associated with distinguished academic hospitals across Europe and North America to run multi-centre trials assessing the long-term clinical efficacy of CyberKnife-based radiosurgery in brain metastases and prostate cancers.

Varian to roll out integrated oncology software to aid CyberKnife treatments.

In February 2025, Varian Medical Systems, a Siemens Healthineers company, launched an integrated software suite aimed at enhancing interoperability between imaging platforms and CyberKnife treatment systems, thus decreasing planning time and increasing treatment accuracy.

Brainlab works with research institutions in accelerating adaptive radiosurgery.

In August of 2023, Brainlab AG collaborated with multiple cancer research institutions to begin the exploration of adaptive treatment techniques within CyberKnife systems, with the goal of dynamically personalising treatment plans based on tumour response data.

Zap Surgical Systems has received FDA clearance for its next-gen robotic radiosurgery unit.

In May 2024, Zap Surgical Systems received FDA clearance of its Zap-X Gyroscopic Radiosurgery system, a direct competitor with CyberKnife technology in the neurosurgical radiosurgery market.

Market Dynamics

The world's effort needs to be in the direction of promising research advancement and improvement in radiotherapy technique.

These phenomena in extra open-up use are an increase in patient reluctance to spend periods in the hospital, creating high public demand for such procedures dependence on long stays in the hospital.

Implementation of incentives and other regulations would boost the market.

Countries and health bodies have started recognising robotic radiosurgery as a major area in oncology treatment. Exceptions regarding the reimbursement structures, as well as fast FDA/CE approval, exist in places such as the USA and Europe, allowing for quick installations. This regulatory momentum creates the push needed to adopt in developing markets that were previously denied on reimbursement grounds.

Most hospitals cannot afford the very large capital investments

Although the CyberKnife has significant clinical benefit potential, it is a capital-intensive investment. Funding for acquiring such high-end equipment is a big challenge for most hospitals in the developing world. The operational costs of maintenance and personnel training only complicate this problem further.

Medical tourism and opening up outpatient centres

On the outpatient front, the upscale investments into medical tourism are coalescing into fresh demand pockets. The fresh demand pockets that are emerging through Invest in Now and the emerging economies in Asia-Pacific and the Middle East will use CyberKnife adoption not only to build capacities for domestic demand but also to attract international patients in wealthier countries.

The future of radiosurgery will be more about AI combined with robotics and image guidance.

The integration of innovative developments, including artificial intelligence, real-time imaging, and adaptive treatment models, will revolutionise the CyberKnife system's treatment paradigm in oncology. This will increase accuracy, shorten treatment cycles, and improve patient outcomes, ensuring longer sustainability of the market.

Attractive Opportunities in the Market

AI-Driven Workflows – AI-enhanced planning and imaging boost treatment accuracy and clinical efficiency.
Medical Tourism Growth – CyberKnife adoption in Asia and the Middle East supports global patient inflow.
Outpatient Facility Expansion – Ambulatory centres are rapidly integrating robotic radiosurgery services.
Cancer Prevalence Surge – Rising global cancer incidence ensures long-term demand for CyberKnife.
Collaborative Research Models – Partnerships with hospitals accelerate adaptive treatment advancements.
Reimbursement Acceleration – Growing insurance coverage and policy support drive wider accessibility.
Emerging Market Penetration – Expanding installations in APAC and LAMEA spur fresh revenue streams.
Integration with Imaging Systems – Interoperability with MRI/CT enhances treatment planning precision.
FDA and CE Approvals – Regulatory clearances enable faster clinical adoption across key regions.
Patient-Centric Innovation – Shorter recovery times strengthen patient preference over invasive methods.

Report Segmentation

By Application: Tumour, Cancer, Vascular Malformation

By End Use: Hospitals, Outpatient Facilities, Research & Manufacturing

By Region: North America (U.S., Canada, Mexico), Europe (UK, Germany, France, Spain, Italy, Spain, Rest of Europe), Asia-Pacific (China, India, Japan, Australia, South Korea, Rest of Asia-Pacific), LAMEA (Brazil, Argentina, UAE, Saudi Arabia (KSA), Africa Rest of Latin America)

Key Market Players

Accuray Incorporated, Elekta AB, Varian Medical Systems (Siemens Healthineers), Brainlab AG, ViewRay Inc., Zap Surgical Systems, GE Healthcare, Hitachi Ltd., Philips Healthcare, and Mevion Medical Systems.

Report Aspects

Base Year: 2024
Historic Years: 2022, 2023, 2024
Forecast Period: 2024-2035
Report Pages: 293

Dominating Segments

By then, CyberKnife would have treated a major segment of tumours as the oncology burden increases all over the world.

CyberKnife has transformed the health care landscape, with more patients and health practitioners calling for solutions that balance efficacy with quality of life. Cancer remains the driving force behind CyberKnife adoption. Several types of cancer, especially prostate, lung, and brain cancers, account for the largest share of cases treated with CyberKnife systems. The high level of sophistication involved in this device-hypofractionated-targeted treatment, which does not require invasive procedures or long recovery times, makes this modern oncology so indispensable.

Non-invasive radiosurgery applications for tumours are becoming a hot trend.

Benign and malignant tumours in delicate areas such as the brain and spine have been examples of the major clinical drivers of CyberKnife. This was the reason why neurosurgeons and oncologists opted for this system. Patients under CyberKnife treatment for AVMs or similar vascular problems should benefit most from low-risk nonsurgical methods. This significant increase in the use of CyberKnife has also been seen at hospitals worldwide, most of which do not have resource options for more complex treatments.

Changing vascular malformations to a niche but important application

Vascular malformation treatment is gradually growing with CyberKnife, although it has a small contribution to the total revenue of the market. Precision radiosurgery that benefits patients who have arteriovenous malformations (AVMs) and other vascular anomalies provides a safer alternative to conventional surgery. Along with research on long-term effectiveness, this segment shows a lot of promise for high growth over the course of the forecast period.

Hospitals take up a dominant share of CyberKnife installations among end-use settings.

Hospitals continue to be the leading adopters of CyberKnife systems, given their capability to fund higher levels of capital investments as well as their potential to tie together multidisciplinary oncology departments. Such institutions that adopt this forward-looking approach are typically leading cancer institutes or academic hospitals, aided by grants, government investments, and research collaborations.

Outpatient facilities will now grow fast, thanks to low-cost delivery models.

Outpatient centres have sprung up as one of the fastest-growing end-use segments as health systems attempt to decentralise high-cost treatments. With CyberKnife treatment cycles becoming shorter and requiring fewer inpatient days, the system is becoming ever more suited to outpatient adoption, increasing both patient and provider attraction.

Research institutes and device manufacturers drive the innovation pipeline

Further, research institutions and device manufacturers are at the forefront of expanding the clinical indications for CyberKnife and fine-tuning the treatment. Such institutions are facilitating knowledge transfer and propelling product innovation through multicenter trials and investments in adaptive radiosurgery protocols.

Key Takeaways

Cancer Care Leadership – Oncology applications dominate due to precision-focused treatment demand.
Hospital Segment Strength – Hospitals remain the core adopters of CyberKnife installations worldwide.
Outpatient Growth Surge – Ambulatory centres are emerging as fast-growing treatment providers.
Tumour Applications Rising – Radiosurgery adoption expands for complex brain and spine tumours.
Vascular Malformation Potential – Expanding treatment scope promises niche but critical market growth.
APAC Growth Momentum – Infrastructure investments accelerate CyberKnife installations across Asia-Pacific.
AI-Powered Precision – Integration of artificial intelligence enhances treatment planning and delivery.
Regulatory Acceleration – Faster FDA and CE approvals improve adoption rates in developed markets.
Medical Tourism Boost – Patient inflow in APAC and the Middle East fuels regional adoption growth.
Innovation Pipeline Strong – Research collaborations drive next-generation radiosurgery advancements.

Regional Insights

Even on CyberKnife for Oncology Support, North America remains at the head of CyberKnife adoption.

CyberKnife is a dominant area in the North American region, primarily due to the US's mature oncology settings, increasing cancer incidence, and favourable reimbursement policies. Continuous adoption and usage are ensured by the presence of key manufacturers and the existence of advanced healthcare institutions. Furthermore, huge investments in AI-based platforms for treatment provision supplement the region's preeminence in precision radiosurgery.

Europe evolves in establishing itself as a greenfield hub for precision medicine and clinical collaborations.

Europe can stand up to having the highest high-technology quality in clinical trials and produces the most innovative medical devices, thus making it in a favourable position to become the largest market for CyberKnife by countries such as Germany, France, and the UK, which invest in formative years in adaptive radiosurgery trials and integrate CyberKnife into the national health system. Regulatory frameworks and other hospital networks for collaboration have an allure in increasing the pace of their adoption in the oncology care pathway.

Asia-Pacific tops the race as the fast-growing region that could witness a significant upsurge in the demand to address cancer care.

APAC will have dramatic growth with increasing cancer incidence, expanding health infrastructure, and government-directed investments in modern oncology care. Leadership within the installations would typically be from Persian China, India, and South Korea, coupling the installation of CyberKnife with medical tourism efforts that would bring in international patients.

LAMEA develops entry prospects for emerging oncology infrastructures in medical tourism.

Latin America, the Middle East, and Africa are adopting the CyberKnife systems with more enthusiasm because of increasing medical tourism to these regions and expanding networks of oncology. While countries like the UAE and Saudi Arabia are engaged in positioning themselves as hubs for international patients, Brazil and Argentina are adopting this technology more gradually under healthcare modernisation programs.

Core Strategic Questions Answered in This Report

What is the expected growth trajectory of the CyberKnife market from 2024 to 2035?

The global CyberKnife market is projected to grow from USD 637.4 million in 2024 to USD 3,792.21 million by 2035, registering a CAGR of 17.6%. This growth is fueled by expanding cancer prevalence, wider adoption in outpatient settings, and increased integration of AI-driven radiosurgery technologies.

Which key factors are fuelling the growth of the CyberKnife market?

Several key factors are propelling market growth:

Rising incidence of cancers and tumours across all major regions
Increasing preference for non-invasive, precision-driven treatment methods
Supportive regulatory frameworks and favourable reimbursement policies
Technological integration of robotics, AI, and imaging systems
Expanding outpatient and medical tourism-driven adoption

What are the primary challenges hindering the growth of the CyberKnife market?

Major challenges include:

High capital expenditure requirements for installation and training
Limited affordability in low-income healthcare markets
Competitive pressure from alternative radiosurgery systems
Technical complexity requiring highly skilled operators
Reimbursement delays in emerging economies

Which regions currently lead the CyberKnife market in terms of market share?

North America currently leads the CyberKnife market due to strong industrial output and oncology innovation. Europe closely follows with leadership in clinical research, while Asia-Pacific is expected to grow fastest due to healthcare infrastructure expansion and rising patient inflow.

What emerging opportunities are anticipated in the CyberKnife market?

The market is ripe with new opportunities, including:

AI and machine learning integration in radiosurgery workflows
Growing adoption across outpatient and ambulatory centres
Expansion into emerging economies with rising cancer burdens
Increasing medical tourism-driven healthcare adoption
Multi-centre research collaborations driving adaptive radiosurgery protocols

Key Benefits for Stakeholders

The report offers a quantitative assessment of market segments, emerging trends, projections, and market dynamics for the period 2024 to 2035.
The report presents comprehensive market research, including insights into key growth drivers, challenges, and potential opportunities.
Porter's Five Forces analysis evaluates the influence of buyers and suppliers, helping stakeholders make strategic, profit-driven decisions and strengthen their supplier-buyer relationships.
A detailed examination of market segmentation helps identify existing and emerging opportunities.
Key countries within each region are analysed based on their revenue contributions to the overall market.
The positioning of market players enables effective benchmarking and provides clarity on their current standing within the industry.
The report covers regional and global market trends, major players, key segments, application areas, and strategies for market expansion. Show more